We are proud to announce the launch of Cardiolinc™ as a non-profit organization (NPO). The Cardiolinc network mission is understand the role of regulatory RNAs in cardiovascular disease and engage in collaborative research to drive the development and growth of precision medicine.
The recently approved COST Action CARDIOPROTECTION will address the challenge to translate new cardioprotective therapies for heart failure discovered in the laboratory setting into the clinical setting.
Cardiolinc member Shizuka Uchida is a guest editor for the upcoming special issue of High-Throughput journal and invites us to revisit the power of microarrays in profiling ncRNAs to facilitate functional studies of these molecules that hold more functions to be discovered. Deadline for submission: December 31.
The 2018 Travel Award for PhD students, postdoctoral fellows, and junior faculty offers a grant to attend a conference of their choice during 2018 related to personalized medicine. Deadline: October 30.
The 13th call for proposals of the Innovative Medicines Initiatives 2 (IMI2) will open with a topic on “Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches”.
The Vascular Biology laboratory at the Technical University in Munich, led by new Cardiolinc member Lars Maegdefessel, is looking for a Postdoctoral researcher with experience in molecular cell biology/physiology.